EuBiologics Co. Ltd.
EuBiologics Co., Ltd., a biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea. It offers inactivated oral cholera vaccine under the Euvichol, Euvichol-Plus, and Euvichol-S names; and EuCorVac-19, a recombinant protein vaccine. The company also provides EcML that is used as a vaccine adjuvant, directly activating antigen … Read more
Market Cap & Net Worth: EuBiologics Co. Ltd. (206650)
EuBiologics Co. Ltd. (KQ:206650) has a market capitalization of $366.19 Million (₩536.18 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13010 globally and #333 in its home market, demonstrating a 3.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EuBiologics Co. Ltd.'s stock price ₩14640.00 by its total outstanding shares 36624236 (36.62 Million).
EuBiologics Co. Ltd. Market Cap History: 2017 to 2026
EuBiologics Co. Ltd.'s market capitalization history from 2017 to 2026. Data shows growth from $132.53 Million to $366.19 Million (12.71% CAGR).
Index Memberships
EuBiologics Co. Ltd. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.17% | #106 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.17% | #106 of 1384 |
Weight: EuBiologics Co. Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
EuBiologics Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EuBiologics Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
EuBiologics Co. Ltd.'s market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.02x
EuBiologics Co. Ltd.'s market cap is 0.02 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $876.71 Million | $39.38 Billion | -$27.57 Billion | 0.02x | N/A |
| 2022 | $222.62 Million | $55.47 Billion | -$1.10 Billion | 0.00x | N/A |
| 2023 | $286.90 Million | $69.37 Billion | -$13.88 Billion | 0.00x | N/A |
| 2024 | $303.91 Million | $96.04 Billion | $19.12 Billion | 0.00x | 0.02x |
Competitor Companies of 206650 by Market Capitalization
Companies near EuBiologics Co. Ltd. in the global market cap rankings as of March 18, 2026.
Key companies related to EuBiologics Co. Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
EuBiologics Co. Ltd. Historical Marketcap From 2017 to 2026
Between 2017 and today, EuBiologics Co. Ltd.'s market cap moved from $132.53 Million to $ 366.19 Million, with a yearly change of 12.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩366.19 Million | +28.87% |
| 2025 | ₩284.15 Million | -6.50% |
| 2024 | ₩303.91 Million | +5.93% |
| 2023 | ₩286.90 Million | +28.88% |
| 2022 | ₩222.62 Million | -74.61% |
| 2021 | ₩876.71 Million | +64.55% |
| 2020 | ₩532.78 Million | +178.87% |
| 2019 | ₩191.05 Million | +31.67% |
| 2018 | ₩145.10 Million | +9.49% |
| 2017 | ₩132.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of EuBiologics Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $366.19 Million USD |
| MoneyControl | $366.19 Million USD |
| MarketWatch | $366.19 Million USD |
| marketcap.company | $366.19 Million USD |
| Reuters | $366.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.